From October 8 to 10, Sichuan Xieli Pharmaceutical Co., Ltd. successfully made its presence felt at the 2024 CPHI World Pharma Ingredients Exhibition in Milan, Italy, achieving remarkable results. As a premier event in the global pharmaceutical industry, CPHI attracts thousands of renowned companies, experts, and industry leaders each year, showcasing cutting-edge products and technologies while exploring future development trends. This exhibition undoubtedly provided an important international platform for Xieli Pharmaceutical to demonstrate its innovation and competitiveness in the active pharmaceutical ingredient (API) sector.
Exhibition Highlights: A Gathering of Global Industry Elites, Xieli Shines Brightly
During the three-day exhibition, Xieli Pharmaceutical's booth saw a steady stream of visitors. The company showcased high-quality API products, including core offerings such as plant extracts and active pharmaceutical ingredients, attracting numerous clients and partners from Europe, America, and Asia for consultations. Through technical displays and face-to-face interactions, Xieli further showcased its leading R&D capabilities and efficient production capacity, particularly its advantages in producing high-purity pharmaceutical components, which received widespread recognition.
This participation was not just a display of Xieli's products and technologies but also a valuable opportunity for deep interaction with global industry elites. The atmosphere at the booth was vibrant, with many clients expressing strong interest in Xieli's API products, especially the technological innovations in plant and animal-based APIs that won favor among international customers.
Collaboration and Development: Multiple International Cooperation Intentions Reached, Expanding Market Footprint
During the exhibition, Xieli Pharmaceutical engaged in in-depth discussions with several well-known pharmaceutical companies and distributors from Europe, the Middle East, and Latin America regarding product cooperation and market expansion. Through face-to-face exchanges, the company reached cooperative intentions with clients, covering various aspects such as API supply chain collaboration, joint research and development of innovative products, and market expansion. This collaboration further supports Xieli's global market positioning, especially in high-growth European and Latin American markets, where the company expects to expand its market share.
Notably, through this exhibition, Xieli not only attracted a substantial number of potential clients but also further strengthened its relationships with existing partners. During the event, the management of Xieli engaged in friendly discussions with several long-term cooperative enterprises, achieving a consensus on deepening collaboration, thereby laying a solid foundation for future win-win development.
Technological Innovation: Promoting Technological Upgrades in the API Sector, Leading the Future of the Industry
Xieli Pharmaceutical adheres to the principle of "Quality First, Innovation Driven," dedicating itself to providing efficient and safe API products for global pharmaceutical companies. At this exhibition, Xieli not only showcased its mature production processes but also shared the latest advancements in technological innovation, including green production technologies, process optimizations to enhance product purity, and integrated management of global supply chains. These innovative measures highlight the company's technological leadership in the field of API production.
In the future, Xieli Pharmaceutical will continue to strengthen its R&D investments, particularly in developing API products that meet international market demands, striving to provide more innovative solutions for the global pharmaceutical industry. By continually upgrading its technology and production capabilities, Xieli is expected to maintain a strong growth momentum in future international market competition.
